Horizon Therapeutics (HZNP) Tops Q4 EPS by 13c, Offers Guidance

Horizon Therapeutics (NASDAQ: HZNP) reported Q4 EPS of $0.56, $0.13 better than the analyst estimate of $0.43. Revenue for the quarter came in at $363.5 million versus the consensus estimate of $348.95 million.

GUIDANCE:

Horizon Therapeutics sees Q1 2020 revenue of $1.4-1.42 billion, versus the consensus of $1.39 billion.

• The Company expects full‐year 2020 net sales to range between $1.40 billion and $1.42 billion, reflecting KRYSTEXXA full-year net sales growth of more than 25 percent and TEPEZZA full-year net sales of $30 million to $40 million. Full-year 2020 adjusted EBITDA is expected to range between $485 million and $500 million, reflecting significant investment in the U.S. launch of TEPEZZA and R&D pipeline programs to drive long-term growth.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
• IBEX Limited (IBEX) Tops Q4 EPS by 6c; offers guidance
• Navan, Inc. (NAVN) Tops Q2 EPS by 1c, Offers Guidance